These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination. Yeshurun D; Abukarshin R; Elias N; Lanir A; Naschitz JE Clin Ther; 1993; 15(2):355-63. PubMed ID: 8519043 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Vanhaecke J; Van Cleemput J; Van Lierde J; Daenen W; De Geest H Transplantation; 1994 Jul; 58(1):42-5. PubMed ID: 8036706 [TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia. Schumacher M; Eber B; Silberbauer K; Breier C; Stühlinger W; Schmidt P; Gaul G; Klein W Acta Med Austriaca; 1992; 19(5):140-4. PubMed ID: 1298143 [TBL] [Abstract][Full Text] [Related]
8. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Gardner SF; Schneider EF; Granberry MC; Carter IR Pharmacotherapy; 1996; 16(3):419-23. PubMed ID: 8726600 [TBL] [Abstract][Full Text] [Related]
9. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046 [TBL] [Abstract][Full Text] [Related]
10. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients. Zambrana JL; Velasco F; Castro P; Concha M; Vallés F; Montilla P; Jimenéz-Perepérez JA; López-Miranda J; Pérez-Jiménez F Am J Cardiol; 1997 Oct; 80(7):836-40. PubMed ID: 9381994 [TBL] [Abstract][Full Text] [Related]
15. Niacin-based therapy for dyslipidemia: past evidence and future advances. Ito MK Am J Manag Care; 2002 Sep; 8(12 Suppl):S315-22. PubMed ID: 12240703 [TBL] [Abstract][Full Text] [Related]
16. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response. Cenarro A; Artieda M; Gonzalvo C; Meriño-Ibarra E; Arístegui R; Gañán A; Díaz C; Sol JM; Pocoví M; Civeira F; Am Heart J; 2005 Dec; 150(6):1154-62. PubMed ID: 16338252 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of once-daily extended-release lovastatin as compared to immediate-release lovastatin in patients with hypercholesterolemia. Lukacsko P; Walters EJ; Cullen EI; Niecestro R; Friedhoff LT Curr Med Res Opin; 2004 Jan; 20(1):13-8. PubMed ID: 14741066 [TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation. Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Jones PH; McKenney JM; Karalis DG; Downey J Am Heart J; 2005 Jan; 149(1):e1. PubMed ID: 15660024 [TBL] [Abstract][Full Text] [Related]
20. Fluvastatin in combination with other lipid-lowering agents. Jokubaitis LA Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]